Microdosing psychedelics in the treatment of ADHD and comorbid disorders
European Psychiatry April 1, 2024 K. P. Kuypers 3 citations
Microdosing psychedelics—taking small, non-hallucinogenic doses of LSD or psilocybin over weeks or months—may enhance certain behaviors, emotions, or treat psychiatric conditions. Recent studies in healthy individuals show nuanced effects on pain perception, mood, neuroplasticity, sleep, brain connectivity, and default mode network synchronicity, though some parameters show null effects after single or repeated administration. Survey research found that people with ADHD reported symptom relief from microdosing, deeming it more effective than conventional treatments. A naturalistic 4-week study with ADHD individuals showed reduced symptoms, increased trait mindfulness, and decreased neuroticism compared to baseline. These results require validation in a clinical trial, which has been conducted and is being analyzed.